FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • March 16th, 2009 • Genvec Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE AGREEMENT (the “Amendment”) is made this 11th day of March, 2009, by and between MOR BEN, LLC, a Maryland limited liability company (“Landlord”), successor-in-interest to MOR Bennington LLLP and GENVEC, INC., a Delaware corporation (“Tenant”).
AMENDMENT NO. 1 TO CHANGE IN CONTROL AGREEMENTChange in Control Agreement • March 16th, 2009 • Genvec Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO CHANGE IN CONTROL AGREEMENT (“Amendment No. 1”) is made, effective as of December 9, 2008, by and between GenVec, Inc., a Delaware corporation (the “Company”), and Paul H. Fischer (“Executive”).
AMENDMENT NO. 1 TO CHANGE IN CONTROL AGREEMENTChange in Control Agreement • March 16th, 2009 • Genvec Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO CHANGE IN CONTROL AGREEMENT (“Amendment No. 1”) is made, effective as of December 9, 2008, by and between GenVec, Inc., a Delaware corporation (the “Company”), and Douglas J. Swirsky (“Executive”).
AMENDMENT NO. 1 TO SALARY CONTINUATION AGREEMENT GENERAL FORM TEMPLATEContinuation Agreement • March 16th, 2009 • Genvec Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO SALARY CONTINUATION AGREEMENT (“Amendment No. 1”) is made, effective as of ____________ __, 2008, by and between GenVec, Inc., a Delaware corporation (the “Company”), and __________ (“Executive”).
AMENDMENT NO. 1 TO SALARY CONTINUATION AGREEMENTSalary Continuation Agreement • March 16th, 2009 • Genvec Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO SALARY CONTINUATION AGREEMENT (“Amendment No. 1”) is made, effective as of December 9, 2008, by and between GenVec, Inc., a Delaware corporation (the “Company”), and Paul H. Fischer (“Executive”).
AMENDMENT NO. 1 TO SALARY CONTINUATION AGREEMENTSalary Continuation Agreement • March 16th, 2009 • Genvec Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO SALARY CONTINUATION AGREEMENT (“Amendment No. 1”) is made, effective as of December 9, 2008, by and between GenVec, Inc., a Delaware corporation (the “Company”), and Douglas J. Swirsky (“Executive”).
